HHS awards Summit Therapeutics $32 to develop new C diff antibiotic

HHS is partnering with Oxford, England-based Summit Therapeutics to develop a new antibiotic to treat Clostridium difficile.

Through the partnership, HHS' Biomedical Advanced Research and Development Authority will give Summit $32 million over two years to conduct two Phase 3 clinical trials of its experimental drug Ridinilazole.

The drugmaker is also eligible to receive a three-year extension on the contract with total potential funding of $62 million.

To learn more about C diff, click here.

More articles on infection control: 
Study suggests possible link between repeat flu vaccination and miscarriage 
Study: Antibiotic use may boost superbug spread in nursing homes 
Pet store puppies sicken 39 people in multistate bacterial outbreak

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


IC Database-3

Top 40 Articles from the Past 6 Months